Sarah B. Goldberg on New Immunotherapy Options for Patients With Lung Cancer
Sarah B. Goldberg, MD, MPH, assistant professor of medicine at Yale Cancer Center, discusses new treatment options for patients with non-small cell lung cancer (NSCLC).
Sarah B. Goldberg, MD, MPH, assistant professor of medicine at Yale Cancer Center, discusses new treatment options for patients with non-small cell lung cancer (NSCLC).
The FDA has approved two immunotherapy agents for NSCLC, nivolumab (Opdivo) and pembrolizumab (Keytruda) as an option for patients who already received one line of chemotherapy that did not work. These two agents work by blocking the PD-1 pathway, which lets the patient's immune system attack the cancer.
FDA Approves Amivantamab-Chemo Combo for Advanced NSCLC
September 19th 2024The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR TKI.
